Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens

European Journal of Heart Failure

Volumn 18, Issue 9, 2016, Pages 1193-1202

  Senni, Michele ^a   McMurray, John J V ^b   Wachter, Rolf ^c   McIntyre, Hugh F ^d   Reyes, Antonio ^e   Majercak, Ivan ^f   Andreka, Peter ^g   Shehova Yankova, Nina ^h   Anand, Inder ⁱ   Yilmaz, Mehmet B ^j   Gogia, Harinder ^k   Martinez Selles, Manuel ^l   Fischer, Steffen ^m   Zilahi, Zsolt ⁿ   Cosmi, Franco ^o   Gelev, Valeri ^p   Galve, Enrique ^q   Gómez Doblas, Juanjo J ^r   Nociar, Jan ^m   Radomska, Maria ^s   Sokolova, Beata ^t   Volterrani, Maurizio ^u   Sarkar, Arnab ^v   Reimund, Bernard ^w   Chen, Fabian ^w   Charney, Alan ^w   more..

^a Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^e HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^f Outpatient Internal Medicine   (Slovakia)

^g Gottsegen Gyorgy Orszagos Kardiologiai Intezet   (Hungary)

^h Cardiology Department   (Bulgaria)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j CUMHURIYET UNIVERSITY   (Turkey)

^k Cardiology Consultants of Orange County   (United States)

^l HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^m Praxis Dr Fischer ^*  (Slovakia)

ⁿ Kardiologiai Szakrendeles   (Hungary)

^o PO Ospedale Valdichiana S Margherita   (Italy)

^p MHAT Tokuda Hospital Sofia   (Bulgaria)

^q HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^r HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^s Letesia sro   (Slovakia)

^t Ambulancia v odbore Vutorne Lekarstvo   (Slovakia)

^u IRCCS SAN RAFFAELE PISANA   (Italy)

^v Novartis HC Ltd   (India)

^w NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

ARNI; Heart failure; LCZ696; Sacubitril; Tolerability; Valsartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM; SACUBITRIL PLUS VALSARTAN;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PARALLEL DESIGN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

EID: 84985994088     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.548     Document Type: Article

References (12)

1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.
2. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013;15:1062–1073.
3. Calvert MJ, Shankar A, McManus RJ, Ryan R, Freemantle N. Evaluation of the management of heart failure in primary care. Fam Pract 2009;26:145–153.
4. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787–1847.
5. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147–e239.
6. ICH harmonised tripartite guideline—guideline for good clinical practice: E6(R1). Geneva: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, June 10, 1996. http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/good-clinical-practice.html (5 October 2014).
7. Declaration of Helsinki: ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/index.html (5 October 2014).
8. MedDRA (2015) MedDRA MedDRA: Medical Dictionary for Regulatory Activities. 2015. Available at http://www.meddra.org/
9. Krum H, McMurray JJ, Abraham WT, Dickstein K, Kober L, Desai AS, Solomon SD, Chiang Y, Gimpelewicz C, Reimund B, Ali MA, Tarnesby G, Massie BM; Committees and Investigators. The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics. Eur J Heart Fail 2015;17:1075–1083.
10. Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L; Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013;15:1173–1184.
11. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685–691.
12. McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs FD, Krum H, Maggioni A, McKelvie RS, Pina IL, Soler-Soler J, Swedberg K. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail 2005;7:710–721.